Stéphane Paul

Title: Innovations of Stéphane Paul in Immunotherapy

Introduction

Stéphane Paul is a notable inventor based in Strasbourg, France. He has made significant contributions to the field of immunotherapy, particularly through his innovative patents. With a total of 2 patents, his work focuses on developing novel therapeutic approaches.

Latest Patents

One of Stéphane Paul's latest patents is related to multifunctional cytokines. This invention involves a novel fusion protein characterized by the formula X—Y or Y—X, where X represents a first immunoregulating polypeptide and Y represents a second immunoregulating polypeptide that is different from X. The patent also encompasses a nucleic acid molecule encoding this fusion protein, as well as a vector containing such a nucleic acid molecule. Additionally, it includes infectious viral particles and host cells that comprise the nucleic acid molecule or vector, along with a process for producing these infectious viral particles. Furthermore, it describes a method for recombinantly producing the fusion protein and a pharmaceutical composition that includes the fusion protein, nucleic acid molecule, vector, infectious viral particles, and host cell, along with their therapeutic uses.

Another significant patent by Stéphane Paul concerns a poxvirus with targeted infection specificity. This invention features a poxviral particle that has a targeted infection specificity conferred by a heterologous ligand moiety present on its surface. This moiety is capable of specifically recognizing and binding to an anti-ligand molecule located on the surface of target cells. The patent also includes a vector that comprises a nucleotide sequence encoding a chimeric polypeptide, which includes the heterologous ligand moiety and part of a natural poxviral surface polypeptide. Compositions that include this poxviral particle or vector are also covered, along with their therapeutic and prophylactic uses, particularly in gene therapy applications aimed at preventing or treating cancer in mammals.

Career Highlights

Stéphane Paul is currently associated with Transgene S.A., a company that specializes in developing immunotherapies for cancer and infectious diseases. His work at Transgene has allowed him to focus on innovative solutions that leverage the immune system to combat diseases.

Collaborations

Throughout his career, Stéphane Paul has collaborated with notable colleagues, including Jean-Marc Balloul and Michel Geist. These collaborations have contributed to the advancement of his research and the development of his